Naltrexone Hydrochloride ( DrugBank: Naltrexone )
8 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 10 | Charcot-Marie-Tooth disease | 20 |
| 40 | Takayasu arteritis | 1 |
| 41 | Giant cell arteritis | 1 |
| 42 | Polyarteritis nodosa | 1 |
| 43 | Microscopic polyangiitis | 1 |
| 44 | Wegener granulomatosis | 1 |
| 45 | Eosinophilic granulomatosis with Polyangiitis | 1 |
| 96 | Crohn disease | 1 |
10. Charcot-Marie-Tooth disease
Clinical trials : 41 / Drugs : 46 - (DrugBank : 9) / Drug target genes : 11 - Drug target pathways : 15
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
40. Takayasu arteritis
Clinical trials : 24 / Drugs : 40 - (DrugBank : 18) / Drug target genes : 23 - Drug target pathways : 110
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
41. Giant cell arteritis
Clinical trials : 131 / Drugs : 139 - (DrugBank : 36) / Drug target genes : 33 - Drug target pathways : 125
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
42. Polyarteritis nodosa
Clinical trials : 15 / Drugs : 26 - (DrugBank : 16) / Drug target genes : 26 - Drug target pathways : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
43. Microscopic polyangiitis
Clinical trials : 88 / Drugs : 81 - (DrugBank : 21) / Drug target genes : 15 - Drug target pathways : 90
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
44. Wegener granulomatosis
Clinical trials : 98 / Drugs : 108 - (DrugBank : 28) / Drug target genes : 22 - Drug target pathways : 81
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
45. Eosinophilic granulomatosis with Polyangiitis
Clinical trials : 31 / Drugs : 44 - (DrugBank : 18) / Drug target genes : 18 - Drug target pathways : 101
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
96. Crohn disease
Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|